Neutralizing chimeric heavy-chain antibody targeting the L-HN domain of Clostridium botulinum neurotoxin type F.
BoNT/F
Heavy-chain antibody
L-HN domain
Phage display library
Journal
Archives of toxicology
ISSN: 1432-0738
Titre abrégé: Arch Toxicol
Pays: Germany
ID NLM: 0417615
Informations de publication
Date de publication:
23 Sep 2024
23 Sep 2024
Historique:
received:
07
07
2024
accepted:
10
09
2024
medline:
23
9
2024
pubmed:
23
9
2024
entrez:
23
9
2024
Statut:
aheadofprint
Résumé
Botulinum toxin (BoNT) from Clostridium botulinum is the most toxic biotoxin known and is also an important bioterrorism agent. After poisoning, the only effective treatment is injection of antitoxin. However, neutralizing nanoantibodies are safer and more effective, representing a promising therapeutic approach. Therefore, it is important to obtain effective neutralizing nanoantibodies. Hence, the present study aimed to construct a phage antibody library by immunizing a camel and screening specific clones that bind to the L-HN domain of BoNT/F and constructing chimeric heavy-chain antibodies by fusing them with a human Fc fragment. The antibodies' affinity and in vivo neutralizing activities were evaluated. The results showed that 2 µg of F20 antibody could completely neutralize 20 × the median lethal dose (LD
Identifiants
pubmed: 39311906
doi: 10.1007/s00204-024-03869-1
pii: 10.1007/s00204-024-03869-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Agarwal R, Schmidt JJ, Stafford RG, Swaminathan S (2009) Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F. Nat Struct Mol Biol 16(7):789–794. https://doi.org/10.1038/nsmb.1626
doi: 10.1038/nsmb.1626
pubmed: 19543288
Ayyar BV, Aoki KR, Atassi MZ (2015a) The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions. Infect Immun 83(4):1465–1476. https://doi.org/10.1128/IAI.00063-15
doi: 10.1128/IAI.00063-15
pubmed: 25624352
pmcid: 4363415
Ayyar BV, Tajhya RB, Beeton C, Atassi MZ (2015b) Antigenic sites on the HN domain of botulinum neurotoxin A stimulate protective antibody responses against active toxin. Sci Rep 5:15776. https://doi.org/10.1038/srep15776
doi: 10.1038/srep15776
pubmed: 26508475
Ben David A, Barnea A, Diamant E et al (2021) Small molecule receptor binding inhibitors with in vivo efficacy against botulinum neurotoxin serotypes A and E. Int J Mol Sci 22(16):8577. https://doi.org/10.3390/ijms22168577
doi: 10.3390/ijms22168577
pubmed: 34445283
pmcid: 8395308
Berger T, Eisenkraft A, Bar-Haim E, Kassirer M, Aran AA, Fogel I (2016) Toxins as biological weapons for terror-characteristics, challenges and medical countermeasures: a mini-review. Disaster Mil Med 2:7. https://doi.org/10.1186/s40696-016-0017-4
doi: 10.1186/s40696-016-0017-4
pubmed: 28265441
pmcid: 5330008
Bomba-Warczak E, Vevea JD, Brittain JM et al (2016) Interneuronal transfer and distal action of tetanus toxin and botulinum neurotoxins A and D in central neurons. Cell Rep 16(7):1974–1987. https://doi.org/10.1016/j.celrep.2016.06.104
doi: 10.1016/j.celrep.2016.06.104
pubmed: 27498860
pmcid: 4988880
Burgin D, Perier C, Hackett G et al (2021) New modified recombinant botulinum neurotoxin type f with enhanced potency. Toxins (Basel) 13(12):834. https://doi.org/10.3390/toxins13120834
doi: 10.3390/toxins13120834
pubmed: 34941672
Chauhan R, Chauhan Kushwah V, Agnihotri S, Vimal M, Saxena N, Dhaked RK (2023) Designing, synthesis and evaluation of derived analogues of selected small molecule non-peptidic inhibitors against serotype BoNT/ F. Toxicon 222:106981. https://doi.org/10.1016/j.toxicon.2022.106981
doi: 10.1016/j.toxicon.2022.106981
pubmed: 36503896
Choudhury S, Baker MR, Chatterjee S, Kumar H (2021) Botulinum toxin: an update on pharmacology and newer products in development. Toxins (Basel) 13(1):58. https://doi.org/10.3390/toxins13010058
doi: 10.3390/toxins13010058
pubmed: 33466571
Dong M, Stenmark P (2021) The structure and classification of botulinum toxins. Handb Exp Pharmacol 263:11–33. https://doi.org/10.1007/164_2019_342
doi: 10.1007/164_2019_342
pubmed: 31792680
Fan Y, Garcia-Rodriguez C, Lou J et al (2017) A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes. PLoS ONE 12(3):e0174187. https://doi.org/10.1371/journal.pone.0174187
doi: 10.1371/journal.pone.0174187
pubmed: 28323873
pmcid: 5360321
Fischer A, Mushrush DJ, Lacy DB, Montal M (2008) Botulinum neurotoxin devoid of receptor binding domain translocates active protease. PLoS Pathog 4(12):e1000245. https://doi.org/10.1371/journal.ppat.1000245
doi: 10.1371/journal.ppat.1000245
pubmed: 19096517
pmcid: 2596314
Gregory KS, Hall PR, Onuh JP, Mojanaga OO, Liu SM, Acharya KR (2023) Crystal structure of the catalytic domain of a botulinum neurotoxin homologue from Enterococcus faecium: potential insights into substrate recognition. Int J Mol Sci 24(16):12721. https://doi.org/10.3390/ijms241612721
doi: 10.3390/ijms241612721
pubmed: 37628902
pmcid: 10454453
Gupta A, Sumner CJ, Castor M, Maslanka S, Sobel J (2005) Adult botulism type F in the United States, 1981–2002. Neurology 65(11):1694–1700. https://doi.org/10.1212/01.wnl.0000187127.92446.4c
doi: 10.1212/01.wnl.0000187127.92446.4c
pubmed: 16344510
Hill KK, Xie G, Foley BT, Smith TJ (2015) Genetic diversity within the botulinum neurotoxin-producing bacteria and their neurotoxins. Toxicon 107(Pt A):2–8. https://doi.org/10.1016/j.toxicon.2015.09.011
doi: 10.1016/j.toxicon.2015.09.011
pubmed: 26368006
Ibrahim H, Retailleau K, Hornby F, Maignel J, Beard M, Daly DM (2024) A novel catalytically inactive construct of botulinum neurotoxin A (BoNT/A) directly inhibits visceral sensory signalling. Toxins (Basel) 16(1):30. https://doi.org/10.3390/toxins16010030
doi: 10.3390/toxins16010030
pubmed: 38251246
Janik E, Ceremuga M, Saluk-Bijak J, Bijak M (2019) Biological toxins as the potential tools for bioterrorism. Int J Mol Sci 20(5):1181. https://doi.org/10.3390/ijms20051181
doi: 10.3390/ijms20051181
pubmed: 30857127
pmcid: 6429496
Kalb SR, Baudys J, Raphael BH et al (2015) Functional characterization of botulinum neurotoxin serotype H as a hybrid of known serotypes F and A (BoNT F/A). Anal Chem 87(7):3911–3917. https://doi.org/10.1021/ac504716v
doi: 10.1021/ac504716v
pubmed: 25731972
pmcid: 4522910
Kosenina S, Martinez-Carranza M, Davies JR, Masuyer G, Stenmark P (2021) Structural analysis of botulinum neurotoxins type B and E by Cryo-EM. Toxins (Basel) 14(1):14. https://doi.org/10.3390/toxins14010014
doi: 10.3390/toxins14010014
pubmed: 35050991
Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5(10):898–902. https://doi.org/10.1038/2338
doi: 10.1038/2338
pubmed: 9783750
Li Z, Lu J, Tan X et al (2022) Functional EL-HN fragment as a potent candidate vaccine for the prevention of botulinum neurotoxin serotype E. Toxins (Basel) 14(2):135. https://doi.org/10.3390/toxins14020135
doi: 10.3390/toxins14020135
pubmed: 35202162
Li Z, Li B, Lu J et al (2023) Biological and Immunological Characterization of a Functional L-HN Derivative of Botulinum Neurotoxin Serotype F. Toxins (Basel) 15(3):200. https://doi.org/10.3390/toxins15030200
doi: 10.3390/toxins15030200
pubmed: 36977091
Liu FJ, Shi DY, Mao YY et al (2020) Immunological characterisation and immunoprotective efficacy of functional domain antigens of botulinum neurotoxin serotype A. Vaccine 38(14):2978–2983. https://doi.org/10.1016/j.vaccine.2020.02.060
doi: 10.1016/j.vaccine.2020.02.060
pubmed: 32113807
Liu M, Li L, Jin D, Liu Y (2021) Nanobody-A versatile tool for cancer diagnosis and therapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol 13(4):e1697. https://doi.org/10.1002/wnan.1697
doi: 10.1002/wnan.1697
pubmed: 33470555
Matsumura T, Amatsu S, Misaki R et al (2020) Fully human monoclonal antibodies effectively neutralizing botulinum neurotoxin serotype B. Toxins (Basel) 12(5):302. https://doi.org/10.3390/toxins12050302
doi: 10.3390/toxins12050302
pubmed: 32392791
Mukherjee J, Ondeck CA, Tremblay JM et al (2022) Intramuscular delivery of formulated RNA encoding six linked nanobodies is highly protective for exposures to three Botulinum neurotoxin serotypes. Sci Rep 12(1):11664. https://doi.org/10.1038/s41598-022-15876-2
doi: 10.1038/s41598-022-15876-2
pubmed: 35803998
pmcid: 9266081
Peck MW, Smith TJ, Anniballi F et al (2017) Historical perspectives and guidelines for botulinum neurotoxin subtype nomenclature. Toxins (Basel) 9(1):38. https://doi.org/10.3390/toxins9010038
doi: 10.3390/toxins9010038
pubmed: 28106761
Pirazzini M, Rossetto O, Eleopra R, Montecucco C (2017) Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev 69(2):200–235. https://doi.org/10.1124/pr.116.012658
doi: 10.1124/pr.116.012658
pubmed: 28356439
pmcid: 5394922
Rasetti-Escargueil C, Popoff MR (2019) Antibodies and vaccines against botulinum toxins: available measures and novel approaches. Toxins (Basel) 11(9):528. https://doi.org/10.3390/toxins11090528
doi: 10.3390/toxins11090528
pubmed: 31547338
Rossetto O, Pirazzini M, Montecucco C (2014) Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol 12(8):535–549. https://doi.org/10.1038/nrmicro3295
doi: 10.1038/nrmicro3295
pubmed: 24975322
Sikorra S, Skiba M, Dorner MB et al (2018) Botulinum neurotoxin F subtypes cleaving the VAMP-2 Q(58)(-)K(59) peptide bond exhibit unique catalytic properties and substrate specificities. Toxins (Basel) 10(8):311. https://doi.org/10.3390/toxins10080311
doi: 10.3390/toxins10080311
pubmed: 30071628
Snow DM, Cobb RR, Martinez J et al (2021) A monoclonal antibody combination against both serotypes A and B botulinum toxin prevents inhalational botulism in a guinea pig model. Toxins (Basel) 13(1):31. https://doi.org/10.3390/toxins13010031
doi: 10.3390/toxins13010031
pubmed: 33466411
Tehran DA, Pirazzini M (2018) Novel botulinum neurotoxins: exploring underneath the iceberg tip. Toxins (Basel) 10(5):190. https://doi.org/10.3390/toxins10050190
doi: 10.3390/toxins10050190
pubmed: 29748471
von Berg L, Stern D, Weisemann J, Rummel A, Dorner MB, Dorner BG (2019) Optimization of SNAP-25 and VAMP-2 cleavage by botulinum neurotoxin serotypes A-F employing taguchi design-of-experiments. Toxins (Basel) 11(10):588. https://doi.org/10.3390/toxins11100588
doi: 10.3390/toxins11100588
Yu YZ, Li N, Wang RL et al (2008) Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Clin Vaccine Immunol 15(12):1819–1823. https://doi.org/10.1128/CVI.00239-08
doi: 10.1128/CVI.00239-08
pubmed: 18845829
pmcid: 2593168
Zornetta I, Azarnia Tehran D, Arrigoni G et al (2016) The first non Clostridial botulinum-like toxin cleaves VAMP within the juxtamembrane domain. Sci Rep 6:30257. https://doi.org/10.1038/srep30257
doi: 10.1038/srep30257
pubmed: 27443638
pmcid: 4957215